ADC Therapeutics Surpasses Revenue Projections with Strong Q3 Results
Wednesday, 13 March 2024, 11:04
ADC Therapeutics Q3 Performance Overview
ADC Therapeutics has reported a Non-GAAP EPS of -$0.97 and revenue of $16.79M, surpassing expectations by $1.53M. This indicates a strong performance for the company in the third quarter.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.